title: Non-Hodgkin's lymphomas, version 2.2014.
abstract: Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Jeremy S
authors.initials: JS
authors.lastname: Abramson
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: C Babis
authors.initials: CB
authors.lastname: Andreadis
authors.forename: Nancy
authors.initials: N
authors.lastname: Bartlett
authors.forename: Naresh
authors.initials: N
authors.lastname: Bellam
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.forename: Richard I
authors.initials: RI
authors.lastname: Fisher
authors.forename: Martha J
authors.initials: MJ
authors.lastname: Glenn
authors.forename: Nancy Lee
authors.initials: NL
authors.lastname: Harris
authors.forename: Richard T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Kelsey
authors.forename: Youn H
authors.initials: YH
authors.lastname: Kim
authors.forename: Susan
authors.initials: S
authors.lastname: Krivacic
authors.forename: Ann S
authors.initials: AS
authors.lastname: LaCasce
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Porcu
authors.forename: Oliver
authors.initials: O
authors.lastname: Press
authors.forename: Rachel
authors.initials: R
authors.lastname: Rabinovitch
authors.forename: Nishitha
authors.initials: N
authors.lastname: Reddy
authors.forename: Erin
authors.initials: E
authors.lastname: Reid
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
authors.forename: Lode J
authors.initials: LJ
authors.lastname: Swinnen
authors.forename: Christina
authors.initials: C
authors.lastname: Tsien
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Nadeem
authors.initials: N
authors.lastname: Zafar
authors.forename: Mary
authors.initials: M
authors.lastname: Dwyer
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D016499:Radioimmunotherapy; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab